openaccessgovernment3 天
An ancient therapy modernized for Clostridioides Difficile therapy
Clostridioides difficile is a type of bacteria that often affects people who have been taking antibiotics, GST Micro LLC ...
The American Journal of Managed Care4 天
Vowst as a Potential Option for Patients With Recurrent C Difficile Infections
The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut ...
The American Journal of Managed Care4 天
Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections
The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile ...
Acurx updates Phase 3 readiness for ibezapolstat in C. difficile Infection
Pharmaceuticals announced updates on Phase 3 Readiness for Ibezapolstat in C. difficile Infection based on recent FDA and EMA ...
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...